Dianthus reports Q3 2026 results, CIDP interim data and MMN enrollment ahead of schedule

Dianthus Therapeutics reported financial results for the quarter ended September 30, 2026, on November 4, 2026, alongside pipeline updates for its complement inhibitor claseprubart and two earlier-stage bifunctional molecules.

In CIDP, an interim responder analysis of the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial found a 75% response rate, exceeding the target response rate of 50% or greater, with results described as consistent and clinically meaningful across multiple efficacy measures.¹ The company said claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of drug-induced lupus, and no related serious adverse events or discontinuations due to safety.¹ Based on this, CAPTIVATE's open-label Part A is now conservatively projected to require fewer than 200 participants to randomize 128 responders into the placebo-controlled withdrawal Part B, with top-line results from all Part A participants expected by year-end 2027 and Part B results expected by year-end 2028.¹

In MMN, the Phase 2 MoMeNtum trial exceeded its original enrollment target of 36 patients, and top-line results from 46 patients remain on track for December 2026, after which a Phase 3 trial in MMN is planned to initiate in 2027.¹ In gMG, the Phase 3 EMERGE registrational trial, evaluating 300mg/2mL subcutaneous dosing every two or four weeks, was initiated in June, with top-line results expected in the second half of 2028.¹ Separately, results from the Phase 2 MaGic open-label extension were presented at the AANEM Annual Meeting from September 29 to October 2, 2026, showing sustained efficacy and a continued favorable safety profile.¹

For the earlier pipeline, dosing of SLE patients in Part B of DNTH212's Phase 1 study in China began in October, with preliminary Part B SLE data expected in the second half of 2027.¹ Part A, evaluating single ascending doses in healthy volunteers, is expected to yield preliminary data in the first quarter of 2027.¹ A Dianthus-led Phase 1 multiple ascending dose study outside China is planned to begin in the second quarter of 2027, with preliminary data expected in the second half of 2027.¹ DNTH312 remains on track to be Phase 1 ready by year-end 2027.¹

On financials, the company reported approximately $1.2 billion of cash, cash equivalents and investments as of September 30, 2026, which it projects will provide runway into 2030.¹